SELLAS Life Sciences Group, Inc. (SLS) Cash flow
Market cap
$552.77M
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | 1 | 1 | 0 | 1 | 0 | 0 | - | - | - | - | - | - | - | - |
| Stock-based compensation | 19 | 20 | 3 | 5 | 2 | 2 | 3 | 0 | 1 | 1 | 1 | 2 | 2 | 2 |
| Cash from operations | -15 | -21 | -29 | -43 | -39 | -33 | -11 | -30 | -18 | -10 | -26 | -24 | -31 | -35 |
| Capital expenditures | -1 | -1 | -1 | -0 | -1 | -0 | - | - | - | - | - | - | - | - |
| Cash from investing | 0 | -0 | -12 | -6 | 10 | -0 | 2 | - | - | - | - | -4 | -5 | - |
| Payments for dividends | - | - | - | - | - | - | - | 0 | - | - | - | - | - | - |
| Repurchases of common stock | 4 | 3 | - | - | - | - | - | - | - | - | - | - | - | - |
| Proceeds from issuance of term debt, net | - | - | 10 | - | - | 23 | - | - | - | - | - | - | - | - |
| Repayments of term debt | - | - | - | - | - | 6 | - | 8 | - | - | - | - | - | - |
| Cash from financing | 71 | 113 | 56 | 24 | 44 | 34 | 6 | 23 | 20 | 38 | 12 | 24 | 22 | 47 |
| Free cash flow | - | - | - | - | - | - | - | - | ||||||
| FCF margin (%) | - | - | - | - | - | - | - | - | - | - | - | - |